Globally, the number of 3D printing patent applications for the pharmaceutical industry declined by 0.3% in Q3 2022 when compared with the preceding quarter. The total number of 3D printing-related grants dropped by 7% in Q3 2022, according to GlobalData’s Patent Analytics.
Notably, 336 3D printing-related patent application in the pharmaceutical industry in Q3 2022 was higher than 337 in previous quarter.
15% of patenting activity came from the top five largest companies
Arkema was the company that filed the most 3D printing patents in the sector of pharmaceutical operations and technologies in Q3 2022. This quarter, Arkema filed 23 3D printing patents, compared to 18 the previous quarter. It was followed by Johnson & Johnson with 10 3D printing patent filings, Jabil (7 filings), and 3D Systems (6 filings) in Q3 2022.
The US accounted for 26% of all patent filings.
In Q3 2022, the US accounted for 26% of 3D printing-related patent filings. China (20%) followed by South Korea (10%). The US represented 1% less of the 27% that it had in Q2 2022.